Category: General

Roche hemophilia drug lowers costs despite high price: ICER

(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

France’s Sanofi buys US hemophilia specialist Bioverativ

France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases.

Payers point to Spark’s gene therapy as a model for innovative pricing plans

When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing.

CMS Considers Alternate Payment Models To Curb Costs On High-Price Treatments, Gene Therapy

“We are trying to do whatever we can to increase competition and give the (health insurance) plans more tools so that they can be better negotiators on our behalf,” Centers for Medicare and Medicaid Services chief Seema Verma tells Reuters. In other CMS news: The agency officially ends two mandatory bundled-payment models and Verma also comments on 1332 waivers.